stars 1 stars 2 stars 3

BioVentrix, Inc. a specialty medical device company serving cardiothoracic surgeons and their patients with lifesaving heart failure therapies. BioVentrix technologies aim to improve cardiac function by directly addressing LV dilation. The BioVentrix Revivent System is designed to support a minimally invasive procedure to treat a dilated left ventricle of patients with ischemic heart failure with reduced ejection fraction (HFrEF) and extensive left ventricular scar, who have a suboptimal response to guideline-directed medical therapy. The procedure uses myocardial micro-anchor implants to reconstruct the dilated left ventricle to produce a more efficient chamber. BioVentrix offers benefits to all stakeholders in heart failure: Patient – improved survival and QOL by treating the underlying cause of HF less invasively Payor – reduced hospitalizations and avoidance of more expensive, highly invasive procedures like transplant and LVAD Provider – become a pioneer in heart failure and offer unique solutions to your patients, in the growing and most expensive disease state in the world

BioVentrix Questions

The BioVentrix annual revenue was $6.4 million in 2026.

David Richmond is the CEO of BioVentrix.

12 people are employed at BioVentrix.

BioVentrix is based in Mansfield, Massachusetts.

The NAICS codes for BioVentrix are [33, 334].

The SIC codes for BioVentrix are [384, 38].

Top BioVentrix Employees

View Similar People
G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users